Pfizer to invest $500M in North Carolina gene therapy plant

Drug giant Pfizer plans to invest $500 million to expand its manufacturing plant in Stanford, N.C., which focuses on gene therapy development, according to EndPoints News.

The expanded facility will add additional capacities and capabilities to support Pfizer's growing gene therapy unit. 

The Sanford-based plant currently manufactures therapies for hemophilia B and Duchenne muscular dystrophy, among other gene therapies. 

The expanded facility will create about 300 jobs.

More articles on pharmacy:
FDA approves AbbVie's $59K rheumatoid arthritis drug
Teva launches generic version of EpiPen for kids
American Regent boosted price of essential hospital product by 1,300%

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months